Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
6.00
-0.04 (-0.66%)
Sep 9, 2025, 4:08 PM HKT
-0.66%
Market Cap18.96B
Revenue (ttm)5.74B
Net Income (ttm)443.69M
Shares Outn/a
EPS (ttm)0.30
PE Ratio42.73
Forward PEn/a
Dividend0.27 (4.50%)
Ex-Dividend DateMay 26, 2025
Volume1,222,000
Average Volume2,196,875
Open6.05
Previous Close6.04
Day's Range5.97 - 6.11
52-Week Range3.15 - 7.26
Beta0.41
RSI44.80
Earnings DateAug 30, 2025

About HKG:9989

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products, such as prolongin, inhixa, neoparin, and heparin and enoxaparin sodium injections; API products, including heparin and enoxaparin sodium APIs; and pan... [Read more]

Sector Healthcare
Founded 1998
Employees 1,926
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9989
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.